title: Excretion of tiapamil in breast milk.
abstract: The excretion of tiapamil in breast milk was studied in six lactating mothers (3-7 days post partum) following a single oral 600 mg dose of the drug. The milk/plasma ratio of tiapamil derived from the areas under the plasma and milk concentration-time curves was 0.44 +/- 0.10 mean +/- s.d.). Assuming an intake of 350 ml of milk during a dosing interval of 12 h, the newborn would be exposed at the maximum to 0.053 mg tiapamil. This small amount does not represent a risk for the baby.
authors.affiliation: Pharma Clinical Research, F. Hoffmann-La Roche & Co. Ltd, Basle, Switzerland.
authors.forename: D
authors.initials: D
authors.lastname: Hartmann
authors.forename: N O
authors.initials: NO
authors.lastname: Lunell
authors.forename: G
authors.initials: G
authors.lastname: Friedrich
authors.forename: A
authors.initials: A
authors.lastname: Rane
mesh_terms: D000328:Adult; D002121:Calcium Channel Blockers / Q000097:blood / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006207:Half-Life; D006801:Humans; D008895:Milk, Human / Q000378:metabolism*; D011437:Propylamines / Q000097:blood / Q000493:pharmacokinetics*; D013976:Tiapamil Hydrochloride
chemical_list: D002121:Calcium Channel Blockers; D011437:Propylamines; D013976:Tiapamil Hydrochloride